Vorinostat

Drug Profile

Vorinostat

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Columbia University; Memorial Sloan-Kettering Cancer Center
  • Developer Banyu; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; Memorial Sloan-Kettering Cancer Center; Merck & Co; Roswell Park Cancer Institute; Stanford University; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Multiple myeloma; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Phase II Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Myelodysplastic syndromes
  • Phase I Glioblastoma; Hodgkin's disease
  • Clinical Phase Unknown Brain metastases
  • No development reported Colorectal cancer
  • Discontinued Gynaecological cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 12 Apr 2016 Stanford University and Merck Sharp & Dohme suspend patient enrolment in a phase II trial in Acute myeloid leukaemia (Newly diagnosed, Combination therapy, Second-line therapy or greater) in USA (NCT01550224)
  • 01 Apr 2016 University of North Carolina at Chapel Hill and Merck complete a phase I/II trial in HIV-1 infections in USA (NCT01319383)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top